KROS is advancing KER-065 for Duchenne muscular dystrophy, with orphan drug status and a phase II trial planned for early 2026.
IBEC researcher Juanma Fernández recently has received funding from the French AFM-Telethon to carry out the project “Monitoring of fibrotic processes in 3D skeletal muscle co-cultures for Muscular ...
A recent study has shed new light on the role of fibro-adipogenic progenitors (FAPs) in muscle regeneration, fibrosis, and degeneration. These cells play a crucial part in tissue homeostasis, and ...
A recent study has shed new light on the role of fibro-adipogenic progenitors (FAPs) in muscle regeneration, fibrosis, and degeneration. These cells play a crucial part in tissue homeostasis, and ...
Gene therapies have extended survival in muscular dystrophy, requiring improved care transitions from pediatric to adult systems. Current systems lack adequate staffing, specialists, and communication ...
The National Center for Health Statistics reports that the percentage of Americans aged 65+ with obesity has doubled to 40% for both men and women. While pharmacotherapies like GLP-1 receptor agonists ...
A new study led by researchers at Hospital for Special Surgery (HSS) suggests that currently available therapies may help control chronic muscle inflammation in Duchenne muscular dystrophy (DMD), a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results